PR83211

EMERYVILLE, California, March 9, 2020 /PRNewswire=KYODO JBN/ --

-- The Opto(TM) Cell Line Development 2.0 workflow, designed for the Beacon(R)

optofluidic instrument, generates in just days the best production cell lines

for complex antibody therapeutics with more than 99% monoclonality assurance

Today, Berkeley Lights, a leader in cell selection, launched a new workflow for

the Beacon instrument: the Opto Cell Line Development 2.0 (Opto CLD 2.0).

While it takes traditional well plate workflows eight to twelve weeks to find clones

producing traditional antibodies, Opto CLD 2.0 enables selection of top clones

secreting complex antibody molecules with superior clonality assurance in less

than one week.

Logo - https://mma.prnewswire.com/media/1078159/Berkeley_Lights_Logo.jpg

The new Opto CLD 2.0 workflow enables measurements of antibody production

across thousands of clones using Berkeley Lights' SpotLight(TM) assays. It targets

different regions of antibody molecules, extending the range of complex antibody

molecules for which top clones can be selected. Screens can also be directed at clones

with specific phenotypes, such as size, viability, or expression of cell-surface markers.

"The last decade has seen an explosion in more complex antibody molecules that

have unique therapeutic functions, such as Fc-engineered mAbs, bispecifics and

multispecifics," said John Proctor, Ph.D., Senior Vice President of Marketing

at Berkeley Lights. "By developing new assays that target different regions of

antibody molecules, Berkeley Lights Opto CLD 2.0 workflow empowers the

selection of top clones secreting both traditional and non-traditional antibody molecules."

Opto CLD 2.0 builds on existing CLD capabilities on the Beacon instrument to

screen and select clones with 1.5–3x higher titers than clones selected by

traditional clone-picking technologies, which by comparison require a slow,

laborious, and inefficient process. Cells can be visually tracked from the

moment they are cloned into NanoPen(TM) chambers through multiple days of

on-chip culture, assay measurements, and clone recovery. Top clones can be

recovered with more than 99% monoclonality assurance and a superior data

package that includes individual visual records of all clones.

The Opto CLD 2.0 workflow will be available for the Beacon instrument in June

2020 and you can find more information here:

https://www.berkeleylights.com/applications/cell-line-development.

About Berkeley Lights

Here at Berkeley Lights, we think cells are awesome! Cells are capable of

manufacturing cures for diseases, fibers for clothing, energy in the form of

biofuels, and food proteins for nutrition. So the question is, if nature is

capable of manufacturing the products we need in a scalable way, why aren't we

doing more of this? Well, the answer is that with the solutions available

today, it is hard. It takes a long time to find the right cell for a specific

job, costs lots of money, and if you have picked a suboptimal cell line, has a

very low process yield. Berkeley Lights has the complete solution to find the

best cells by functionally screening and recovering individual cells for

antibody discovery, cell line development, T cell analysis, and synthetic

biology. Our proprietary technology, including the Beacon(R) and Lightning(TM)

platforms, accelerate the rate you can discover and develop cell-based products

in a fraction of the time and at a fraction of the cost of conventional, legacy

research methods. Using our tools and solutions, scientists can find the best

cells, the first time they look. For more information, visit www.berkeleylights.com.

Berkeley Lights' Beacon and Lightning platforms and Culture Station Instrument

are: For Research Use Only. Not for use in diagnostic procedures.

SOURCE: Berkeley Lights

CONTACT: berkeleylights@bulleitgroup.com